Aliskiren | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Aliskiren
Health Canada Patents

AMI Lifesciences is Driven by Chemistry. Powered by People.

Contact Supplier

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Contact Supplier

Bhavna Laboratories is an API & Intermediate manufacturer focusing on the muscle relaxant & ophthalmic segments.

Contact Supplier

Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

Contact Supplier

Quotient Sciences- Molecule to Cure. Fast.

Contact Supplier

pharmacompass-2-m-2025-08-25

Aliskiren

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

9 API Suppliers, 4 USDMF, 1 EU WC, 3 NDC API, 4 Listed Suppliers

9 API Suppliers
4 USDMF
1 EU WC
3 NDC API
4 Listed Suppliers

DEVELOPMENTS

31 Drugs in Development

31 Drugs in Development

INTERMEDIATES

5 Intermediate Suppliers

5 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

24 FDF Dossiers, 20 FDA Orange Book, 4 Europe

24 FDF Dossiers
20 FDA Orange Book
4 Europe

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 150MG BASE, TABLET;ORAL - EQ 300MG BASE, TABLET;ORAL - EQ 150MG BASE;12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 150MG BASE;25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 300MG BASE;12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 300MG BASE;25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 150MG BASE
TABLET;ORAL - EQ 300MG BASE
TABLET;ORAL - EQ 150MG BASE;12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 150MG BASE;25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 300MG BASE;12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 300MG BASE;25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 SPI Pharma, 6 DKSH, 5 Boai NKY Pharmaceuticals Ltd, 2 Gangwal Healthcare, 1 ACG Worldwide, 3 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 2 Ashland, 22 BASF, 10 Corel Pharma Chem, 2 DFE Pharma, 1 Esteem Industries, 1 Finar, 8 Gangwal Chemicals, 4 Ideal Cures, 11 Kerry, 1 Keval Exports, 3 Kima Chemical, 6 Lonza Capsugel, 10 Microlex e.U, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 3 Novo Excipients, 3 Pharmatrans-Sanaq, 2 Pluviaendo, 2 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 10 Roquette, 6 Seppic, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 9 Sigachi Industries, 2 Silverline Chemicals, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 2 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

40 Coating Systems & Additives, 32 Fillers, Diluents & Binders, 22 Controlled & Modified Release, 19 Thickeners and Stabilizers, 18 Disintegrants & Superdisintegrants, 18 Direct Compression, 17 Granulation, 13 Solubilizers, 12 Lubricants & Glidants, 8 Chewable & Orodispersible Aids, 8 Co-Processed Excipients, 8 Topical, 7 Film Formers & Plasticizers, 5 Empty Capsules, 5 Coloring Agents, 4 Vegetarian Capsules, 4 API Stability Enhancers, 4 Taste Masking, 4 Emulsifying Agents, 4 Rheology Modifiers, 2 Parenteral

40 Coating Systems & Additives
32 Fillers, Diluents & Binders
22 Controlled & Modified Release
19 Thickeners and Stabilizers
18 Disintegrants & Superdisintegrants
18 Direct Compression
17 Granulation
13 Solubilizers
12 Lubricants & Glidants
8 Chewable & Orodispersible Aids
8 Co-Processed Excipients
8 Topical
7 Film Formers & Plasticizers
5 Empty Capsules
5 Coloring Agents
4 Vegetarian Capsules
4 API Stability Enhancers
4 Taste Masking
4 Emulsifying Agents
4 Rheology Modifiers
2 Parenteral

DIGITAL CONTENT

13 News #PharmaBuzz

13 News #PharmaBuzz

GLOBAL SALES INFORMATION

4 US Medicaid Prescriptions, 4 Regulatory FDF Prices, 1 Annual Reports

4 US Medicaid Prescriptions
4 Regulatory FDF Prices
1 Annual Reports

MARKET PLACE

1 APIs, 1 FDF Dossiers

1 APIs
1 FDF Dossiers

PATENTS & EXCLUSIVITIES

14 US Patents, 10 Health Canada Patents

14 US Patents
10 Health Canada Patents

Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

10 All

01 4Gowling Lafleur Henderson LLP

02 6Gowling Strathy & Henderson

filter Patent Reset all filters

10 All

01 102147056

filter Product Reset all filters

10 All

01 2Aliskiren

02 4Aliskiren | Amlodipine Besylate

03 4Aliskiren | Hydrochlorothiazide

filter Dosage Reset all filters

10 All

01 4Film Coated Tablets

02 2Film-Coated Tablets

03 4Tablet

filter Exp Date Reset all filters

10 All

01 102015-04-13

Product Main Page

01

Gowling Strathy & Henderson

Aliskiren

iPHEX India

Not Confirmed

Gowling Strathy & Henderson

Canada

iPHEX India

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2015-04-13

Date Granted : 2005-10-25

Brand Name : RASILEZ

Patent Number : 2147056

Filing Date : 1995-04-13

Strength per Unit : 150mg

Dosage Form : Film-Coated Tablets

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2015-04-13

Date Granted : 2005-10-25

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Gowling Strathy & Henderson

Aliskiren

iPHEX India

Not Confirmed

Gowling Strathy & Henderson

Canada

iPHEX India

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2015-04-13

Date Granted : 2005-10-25

Brand Name : RASILEZ

Patent Number : 2147056

Filing Date : 1995-04-13

Strength per Unit : 300mg

Dosage Form : Film-Coated Tablets

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2015-04-13

Date Granted : 2005-10-25

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

Gowling Strathy & Henderson

Aliskiren, Hydrochlorothiazide

iPHEX India

Not Confirmed

Gowling Strathy & Henderson

Canada

iPHEX India

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2015-04-13

Date Granted : 2005-10-25

Aliskiren, Hydrochlorothiazide

Brand Name : RASILEZ HCT

Patent Number : 2147056

Filing Date : 1995-04-13

Strength per Unit : 150 / 12.5, 150 / 25, 300 / 12.5 and 300 / 25 mg

Dosage Form : Film Coated Tablets

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2015-04-13

Date Granted : 2005-10-25

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

Gowling Strathy & Henderson

Aliskiren, Hydrochlorothiazide

iPHEX India

Not Confirmed

Gowling Strathy & Henderson

Canada

iPHEX India

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2015-04-13

Date Granted : 2005-10-25

Aliskiren, Hydrochlorothiazide

Brand Name : RASILEZ HCT

Patent Number : 2147056

Filing Date : 1995-04-13

Strength per Unit : 150 / 12.5, 150 / 25, 300 / 12.5 and 300 / 25 mg

Dosage Form : Film Coated Tablets

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2015-04-13

Date Granted : 2005-10-25

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

Gowling Strathy & Henderson

Aliskiren, Hydrochlorothiazide

iPHEX India

Not Confirmed

Gowling Strathy & Henderson

Canada

iPHEX India

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2015-04-13

Date Granted : 2005-10-25

Aliskiren, Hydrochlorothiazide

Brand Name : RASILEZ HCT

Patent Number : 2147056

Filing Date : 1995-04-13

Strength per Unit : 150 / 12.5, 150 / 25, 300 / 12.5 and 300 / 25 mg

Dosage Form : Film Coated Tablets

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2015-04-13

Date Granted : 2005-10-25

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

Gowling Strathy & Henderson

Aliskiren, Hydrochlorothiazide

iPHEX India

Not Confirmed

Gowling Strathy & Henderson

Canada

iPHEX India

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2015-04-13

Date Granted : 2005-10-25

Aliskiren, Hydrochlorothiazide

Brand Name : RASILEZ HCT

Patent Number : 2147056

Filing Date : 1995-04-13

Strength per Unit : 150 / 12.5, 150 / 25, 300 / 12.5 and 300 / 25 mg

Dosage Form : Film Coated Tablets

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2015-04-13

Date Granted : 2005-10-25

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

07

Gowling Lafleur Henderson LLP

Aliskiren, Amlodipine Besylate

iPHEX India

Not Confirmed

Gowling Lafleur Henderson LLP

Canada

iPHEX India

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2015-04-13

Date Granted : 2005-10-25

Aliskiren, Amlodipine Besylate

Brand Name : RASILAMLO

Patent Number : 2147056

Filing Date : 1995-04-13

Strength per Unit : 150 / 5 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2015-04-13

Date Granted : 2005-10-25

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

08

Gowling Lafleur Henderson LLP

Aliskiren, Amlodipine Besylate

iPHEX India

Not Confirmed

Gowling Lafleur Henderson LLP

Canada

iPHEX India

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2015-04-13

Date Granted : 2005-10-25

Aliskiren, Amlodipine Besylate

Brand Name : RASILAMLO

Patent Number : 2147056

Filing Date : 1995-04-13

Strength per Unit : 150 / 10 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2015-04-13

Date Granted : 2005-10-25

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

09

Gowling Lafleur Henderson LLP

Aliskiren, Amlodipine Besylate

iPHEX India

Not Confirmed

Gowling Lafleur Henderson LLP

Canada

iPHEX India

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2015-04-13

Date Granted : 2005-10-25

Aliskiren, Amlodipine Besylate

Brand Name : RASILAMLO

Patent Number : 2147056

Filing Date : 1995-04-13

Strength per Unit : 300 / 5mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2015-04-13

Date Granted : 2005-10-25

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

10

Gowling Lafleur Henderson LLP

Aliskiren, Amlodipine Besylate

iPHEX India

Not Confirmed

Gowling Lafleur Henderson LLP

Canada

iPHEX India

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2015-04-13

Date Granted : 2005-10-25

Aliskiren, Amlodipine Besylate

Brand Name : RASILAMLO

Patent Number : 2147056

Filing Date : 1995-04-13

Strength per Unit : 300 / 10 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2015-04-13

Date Granted : 2005-10-25

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!